The haemodynamic effects of a new pl-receptor agonist, 1-(4 hydroxyphenoxy) 3-isopropylamino-2-propanol, were studied in 25 patients after acute myocardial infarction using non-invasive methods. The drug caused an increase in systolic blood pressure and pulse pressure, without change in diastolic blood pressure, and a slight increase in heart rate and reduction in the pre-ejection period. These changes were greater in patients without a history of left heart failure. It is suggested that this cardioselective drug possesses positive inotropic activity but only slight positive chronotropic activity. The substance has been further investigated as a possible antidote to unwanted cardiac side effects of the cardioselective p-blocker, metoprolol. The changes in the cardiovascular dynamics caused by metoprolol in patients with acute myocardial infarction were promptly reversed by this new PA-agonist.
and Knaus et al. (1978) . Preliminary investigations of their haemodynamic effects, using non-invasive methods in healthy subjects (Johnsson et al., 1979) , showed a significant shortening of the pre-ejection period (PEP), left ventricular ejection time (LVET), and electromechanical systole, and a rise in the systolic blood pressure. There were no great changes in heart rate or diastolic blood pressure when the racemic form was given as an intravenous infusion in doses up to 20 ,ug per kg body weight or in oral doses of 2-5 to 20 mg. These findings indicate a selective inotropic action, making the substance a useful pharmacological agent to support a myocardium whose function has been depressed by myocardial infarction or myocardial depressant drugs.
Using non-invasive methods, the haemodynamic effects of the racemic form were studied in patients in a stable phase following acute myocardial infarction. The effects of the laevo form were also studied in patients with acute myocardial infarction after previous intravenous injection of the cardioselective r-blocker metoprolol, to evaluate the drug as a possible antidote to unwanted cardiac effects of 5-blocking agents.
Methods
With their informed consent, 25 patients with stable acute myocardial infarction were given 1-(4 hydroxyphenoxy)-3-isopropylamino -2-propanol, using non-invasive procedures. The laevo form of the compound (H 133/22 ) is twice as potent as the racemic form (H 80/62). The diagnosis ofmyocardial infarction was based on a typical clinical picture, definite electrocardiographic infarct patterns, and an increase in serum levels of cardiac enzymes (e.g. aspartate aminotransferase, AST). Patient data are shown in Tables 1 and 2 .
The first part of the study comprised 15 patients (Table 1) , aged from 50 to 80 years, investigated at 2-5 to 21 days from the onset of chest pain. Nine of these patients had a previous history of left ventricular failure and were on diuretics and/or digitalis, but were not in heart failure at the time of the study. None was on r-blocker therapy. After a control period of 20 minutes, to achieve steady state conditions, H 80/62 was infused initially in a dose of 40 to 50 ,ug per kg body weight. Later, 40 to 50 jig per kg was infused, to give a total dose of 80 to 100 jig per kg body weight. Heart rate was calculated from a continuous electrocardiographic recording, using an average rate during the last 5 minutes before the drug infusion as the control value. Heart rate after infusion of the drug was calculated as mean heart rate during a 5-minute period after completed drug infusion. The blood pressure was measured indirectly every 2 minutes with an ultrasound sphygmomanometer (Arteriosonde 1217, Hoffman La Roche, Inc., Cranbury, USA), which has been shown to give readings which correlate well with the invasively measured blood pressure (Hochberg and Salomon, 1971; George et al., 1975 (Fabian et al., 1972; Waagstein et al., 1974) and was corrected for heart rate to derive pre-ejection period index (PEPI) (Weissler and Garrard, 1971; Weissler et al., 1972) as an index of myocardial performance.
In the second part of the study, 10 patients with acute myocardial infarction ( After the infusion was completed, the patients were monitored until their heart rate and blood pressure reached a steady state. Heart rate, systolic and diastolic blood pressures, pre-ejection period, and pre-ejection period index were measured in the control period, 10 minutes after metoprolol, and 15 and 60 minutes after the end of H 133/22 infusion. The cardiac output was estimated from heart rate and stroke volume, using impedance cardiography (Instrumentation for Medicine, Model 304 A), which has been found to give results which correlate well with those obtained by the Fick method (Naggar et al., 1975 heart failure; i =mean -SE. a significant but small rise in heart rate and in 2 patients a greater increase was seen ( Fig. 3 and 4 ; Table 3 ). The pre-ejection period was shortened significantly from the control value ( Fig. 5 and 6 ; Table 3 ). These changes were already evident at the lower concentration but were larger at the higher dose level. The absence of change in the diastolic blood pressure suggests that the drug has no significant peripheral effect. The decrease in the pre-ejection period corroborates the previous findings in healthy human subjects and indicates positive inotropic activity.
The responses of the patients with acute myocardial infarction with a history of left heart failure (group 2) were compared with those ofpatients without left heart failure (group 1) after a dose of 40 to 50 ,ug per kg body weight of the drug (Table 4 ). In group 1 there was a significant increase in the pulse pressure and a shortening of the pre-ejection period without significant increase in heart rate. In group 2, however, an increase in the pulse pressure was seen without shortening of the pre-ejection period. Heart rate in this group was significantly increased. The higher dose, 80 to 100 ,ug per kg Metoprolol, a cardioselective n-blocker, in a dose of 15 mg given intravenously, reduced heart rate, systolic and diastolic blood pressures, and pulse pressure (Table 5) . It prolonged the pre-ejection period by 9-8 per cent ( Fig. 7 ; Table 5 ) and caused a reduction in cardiac output with no significant alteration in the stroke volume ( Fig. 8  and 9 ). Fifteen minutes after the infusion of H 133/22 (50 ,ug per kg body weight during 5 minutes), a significant reversal of the effects of metoprolol was achieved with an increase in heart rate, systolic and diastolic blood pressures, and pulse pressure, and a reduction of the pre-ejection period ( Fig. 7 ; Table 5 ). Stroke volume was unchanged except in 2 patients (cases 1 and 4), who showed a large increase 15 minutes after the infusion; at 60 minutes the stroke volume returned to the previous level (after metoprolol) in these patients (Fig. 9) . Cardiac output increased in all Fig. 7 Changes in pulse pressure, heart rate, blood pressure, and pre-ejection period index (PEPI) in 10 patients with acute myocardial infarction after infusion of metoprolol (15 mg Table 5 ). All other measurements were also the same 15 and 60 minutes after H 133/22 (Fig. 7-9 ) as during the control period.
III: ELECTROCARDIOGRAPHIC CHANGES AND SIDE EFFECTS
No arrhythmias or conduction abnormalities were observed in any of the patients before or after the administration of the inotropic compounds during continuous electocardiographic recording. There were no signs of reinfarction in any of the patients as judged from symptoms, repeated daily electrocardiographic recordings, and enzyme analyses. The positive inotropic agent caused no other symptoms and was thus well tolerated.
Discussion
anges in cardiac output in 10 patients with irdial infarction after infusion of In the first part of this investigation, the haemo-(M) and H 133/22 (H), as given in Fig. 7 .
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-3-isopropylamino-2-propanol (H 80/62) were studied on patients with acute myocardial infarction using non-invasive methods. The results showed an improvement in cardiac contractility, as shown by a reduction in the pre-ejection period, an increase in heart rate, and a rise in the systolic blood pressure and pulse pressure, effects similar to those of other 4 (3-adrenergic agonist compounds (Harris et al., 1967; Krasnow, 1971; Weissler and Garrard, 1971) . In contrast to isoprenaline, which has both cardiac (ftJ) and peripheral (A2) effects, H 80/62 did not affect the peripheral vessels, as shown by an unchanged diastolic blood pressure, as was noted by Carlsson et al. (1977) (Newman, 1977) . (before metoprolol) In the second part of the study, the infusion of 9. In acute myocardial infarction, n-blocking drugs are administered to counteract the harmful effect of increased endogenous catecholamines on cardiac metabolism and cardiac work (Maroko et al., 1971; Videbaek et al., 1972; Waagstein and Hjalmarson, 1975; Waldenstr6m et al., 1978) . Under certain circumstances, however, an unexpected depression of cardiac performance may occur, resulting in a drop in blood pressure and cardiac output, requiring immediate treatment. It has been found that Pblocking drugs are effective in controlling angina pectoris (Ekelund et al., 1976) , reducing ischaemic injury (Maroko et al., 1971; Reimer et al., 1973; Waagstein et al., 1974; Gold et al., 1976) , controlling hypertension and certain arrhythmias (Jewitt and Singh, 1974) , and in treatment of hyperkinetic circulatory states (Frohlich, 1971 ). An increasing number of patients on chronic n-blocker treatment will therefore be seen in emergency situations, such as acute myocardial infarction during surgical procedures. Sudden withdrawal of the r-blocker removes its protective effect on the ischaemic myocardium and its preventive effect against arrhythmias. The sudden withdrawal of (-blockers may be harmful (Miller et al., 1975) . The present investigation indicates that 5-blocker treatment does not necessarily have to be withdrawn abruptly in these patients in emergency situations since an effective antidote is available for prompt reversal of the unwanted depression of cardiac function by (-blockade.
Isoprenaline and noradrenaline have been widely used to reverse the adverse effects of (-blocking agents. In a recent study it was found that dobutamine could reverse all the effects of the (-blocking agent metoprolol in patients with acute myocardial infarction (Waagstein et al., 1978) . From animal experiments (Robie et al., 1974) it is known that dobutamine, in addition to its (l-stimulating action, also has a-receptor and P2-receptor stimulating effects. Low or moderate doses of dobutamine have balanced effects on vasoconstriction and vasodilatation with small changes in peripheral vascular resistance (Akhtar et al., 1975; Loeb et al., 1975 The effective reversal of the cardiovascular effects of metoprolol by H 133/22 makes it valuable in counteracting the cardiodepressant effect of (-blockers, especially P,-blocking agents. Because of its greater inotropic than chronotropic effect, it may be of value also in the treatment of congestive heart failure and hypotension. The combination of digitalis and H 133/22 with balanced effects on heart rate and optimal positive inotropic stimulation seems promising for the long-term treatment of patients with heart failure. The lack of arrhythmogenic properties also makes it useful in the treatment of extreme bradycardia and atrioventricular conduction. A special advantage of this inotropic agent compared with others available is that the drug can be given orally. Studies of the clinical value of the drug in acute and long-term treatment are in progress. 
